Fig. 6

Heterogeneity in drug sensitivity, immunotherapeutic response and genetic mutation between low- and high-risk HCC patients in TCGA-LIHC cohort. A Difference in IC50 of small molecular agents between low- and high-risk patients. B Immune checkpoints with significant difference between groups. C-F Comparison of CTA, T cell inflamed score, TIDE score and TMB between groups. G Waterfall plot illustrating the major mutated genes in high-risk group. H Waterfall plot exhibiting the major mutated genes in low-risk group. I Interactions between mutated genes across high-risk patients. J Interactions between mutated genes across low-risk patients. K, L Comparison of the mutation frequency between low- and high-risk groups. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns: no significance